ArticleProstate cancer2025
MRI-Determined Tumor Contact Area as a Predictor of Pathological Extraprostatic Extension in Clinical T2 Prostate Cancer.
Article in Prostate cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- MRI-Determined Tumor Contact Area as a Predictor of Pathological Extraprostatic Extension in Clinical T2 Prostate Cancer.Prostate cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the validity of magnetic resonance imaging-determined tumor contact area (MRI-TCA) as a predictive factor for pathological extraprostatic extension (EPE) in cT2N0M0 prostate cancer patients. Methods: We retrospectively analyzed 72 cT2N0M0 prostate cancer patients who underwent multiparametric MRI (mpMRI) followed by robot-assisted laparoscopic prostatectomy (RARP) between February 2014 and April 2021. Patients whose MRI-based index lesion did not match the pathological specimens were excluded. MRI-TCA was approximated using an elliptical shape and calculated by two different methods: MRI-TCA1: Calculated using the tumor contact length (TCL) in the axial plane and the longer TCL in either the sagittal or coronal plane, capturing tumor dimensions across two planes. MRI-TCA2: Calculated using the TCL in the axial plane and tumor thickness derived from MRI slice data, reflecting the tumor's contact area within the MRI volume. We compared postoperative prostate-specific antigen (PSA) recurrence-free survival by stratifying patients based on the optimal thresholds of MRI-TCL, MRI-TCA1, MRI-TCA2, pathological-TCL, and pathological-TCA. Results: Sixteen patients (22.2%) were pathologically positive for EPE. MRI-TCL, MRI-TCA1, and MRI-TCA2 were significantly greater in patients with EPE-positive (EPE+) tumors than in those with EPE-negative (EPE-) tumors ( Conclusion: Both MRI-TCA1 and MRI-TCA2 are clinically accessible and effective parameters for predicting pathological EPE in cT2N0M0 prostate cancer patients. However, neither method demonstrated clear superiority over MRI-TCL. Pathological-TCA was shown to be a significant predictor of both pathological EPE and postoperative PSA recurrence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.